Core Viewpoint - The article emphasizes the transformative potential of the pharmaceutical and healthcare industry, highlighting the integration of AI technology, the global expansion of Chinese pharmaceutical innovations, and the commitment to deepening investment in the sector as key drivers for future growth [3][4][6][7]. Group 1: AI Empowerment in Pharmaceutical Innovation - AI is reshaping the pharmaceutical industry by significantly reducing research and development cycles and costs, addressing traditional challenges of high investment and long timelines [4][5]. - The integration of AI in drug discovery, clinical trial design, and production processes is seen as a new paradigm that enhances the industry's productivity and innovation capabilities [4][5]. Group 2: Global Expansion of Chinese Pharmaceutical Innovations - 2025 is identified as a pivotal year for Chinese pharmaceutical companies, marking a transition from quantity to quality in global markets, with total foreign licensing transactions exceeding $130 billion and over 150 deals [6]. - Chinese companies are increasingly recognized as equal partners in global pharmaceutical competition, with significant collaborations such as the $12 billion partnership between Heng Rui Medicine and GSK [6]. Group 3: Commitment to Investment in the Pharmaceutical Sector - The investment landscape in the pharmaceutical sector is evolving, with a projected financing total of approximately 122.78 billion yuan in 2025, reflecting a 46.41% year-on-year increase [7]. - The focus remains on early-stage, innovative, and high-quality companies, particularly in areas like AI drug development and advanced medical devices, to foster growth and innovation [7][8].

2026：于临界处坚守，在折叠处重构展望 2026年，技术的快速迭代必将伴随路线的激烈竞争与优胜劣汰。我们怀抱审慎的乐观，坚信中国经 济的深厚底蕴与科技创新的巨大潜能。那些在实验室里酝酿的惊奇，在生产线上升级的工艺，终将 汇聚成推动社会进步的磅礴力量。 CAN PART ? 骏 马 启 新 · 创 赢２０２６ 证券时报。全国创投协会联盟 National Alliance of Vanture Capilal Associations 業 本书出印 科创星创始合伙 2025年，是新一轮科技革命的关键节点。我国的"十五五" 规划建议 与美国的"创世纪计划"，不约 而同地将人工智能、光子、量子、商业航天、脑机接口、可控核聚变和合成生物学等前沿技术列为 国家发展的核心目标。这标志着未来的全球竞争与发展轨迹，正清晰地向着这些硬核领域进发。 我们清晰地看到，经过过去十年的潜心摸索与积累，硬科技已度过缓慢的爬坡期，正站在加速爆 发、指数增长的临界点之上。 锚定长期：在深度调整中聚焦核心价值 2025年，也是中国创投行业经历深度调整后，走向复苏与坚定转型的一年。市场的逻辑从未如此清 晰：唯有回归"投早、投小、投长期、投硬科 ...

Core Insights - The report titled "Synthetic Biology Industry & Investment Strategy Research Report" provides a comprehensive analysis of the synthetic biology sector, covering technical pathways, market landscape, representative companies, industrial clusters, and policy trends [2]. Group 1: Company Overview - Zhejiang Jintou Shengyuan Equity Investment Co., Ltd. was established in June 2023 with a registered capital of 200 million yuan, serving as a market-oriented equity investment platform under the Zhejiang Provincial Innovation Investment Group [6]. - The company focuses on sectors such as new materials, new technologies, and biomedicine, with a total fund scale exceeding 10 billion yuan [6][34]. - Jintou Shengyuan aims to enhance the operational efficiency of provincial government industrial funds and contribute to the modernization of the industrial system in Zhejiang [34]. Group 2: Market Dynamics - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%, and is projected to reach nearly $50 billion by 2028 [25]. - The Chinese market is expected to reach approximately 10 billion yuan in 2024, continuing to grow to 12.406 billion yuan in 2025 [25]. Group 3: Technological Advancements - Shanghai Kasei Biotechnology Co., Ltd. has pioneered the large-scale production technology of long-chain dicarboxylic acids through biological methods since 2003, breaking the monopoly of chemical synthesis [7]. - Ginkgo Bioworks, established in 2008, has expanded its offerings into life science tools and services, integrating various foundational tools to assist downstream clients in producing biological products [14][15]. Group 4: Investment Strategies - The report emphasizes the importance of strategic partnerships and collaborations in the synthetic biology sector to enhance research capabilities and market penetration [15][16]. - The investment landscape is characterized by a shift from pure service models to integrated solutions that combine research services with product offerings, driven by advancements in AI and automation [15][16].

在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 承办单位 | 享融智云 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 ↓↓↓ 论坛设置 0 2 拟定话题 0 3 *以大会现场实际议程为准 商务合作 ...

纳斯达克上市公司PFAI正式入驻深港科技创新合作区—港深创科园，启动建设合成生物学实验室 及"PFAI国际生物技术创新协同中心"，其首个落地项目"人源乳铁蛋白"也开始进入中试放大阶段。这一 里程碑事件，不仅彰显了国际前沿生物企业对河套创新生态的高度认可，更与2026年深圳市政府工作报 告中关于河套发展的战略部署同频共振，为深港协同创新注入强劲动能。 更值得期待的是，PFAI的入驻将形成"高端平台+核心技术+国际资源"的聚合效应。其国际化研发团队 与资本背景，将与河套已有的国家人工智能学院深圳河套学院、中科院香港创新院基地等平台形成交叉 协同，推动"AI+生物"融合创新。同时，项目将受益于河套科研货物免税、跨境人员便利等政策红利， 加速研发与产业化进程。 深圳正以河套为支点，撬动深港科技一体化发展。PFAI作为国际生物创新企业率先落子，不仅为自身 发展开辟新空间，也为更多全球顶尖科技企业提供了"来华创新"的示范路径。随着新皇岗口岸启用、跨 境通道完善，河套的"磁吸力"将持续增强。 未来，河套深港科技创新合作区有望成为全球合成生物学与生物技术创新的重要策源地。PFAI的先行 实践，正为这一愿景写下有力注脚。在政策 ...

大会介绍 0 1 大会时间 | 2026年3月31日-4月1日 大会地点 | 杭州市 大会规模 | 1000人 主办单位 | synbio深波 在全球推进绿色转型与"双碳"目标的战略背景下，生物基化学品与材料作为生物制造产业的核心支 柱，凭借原料可再生、全生命周期低碳环保等核心优势，正加速替代传统石油基产品，在包装、纺 织、汽车等领域展现出广阔应用前景，成为全球产业绿色转型的关键赛道。 我国高度重视该领域发展，将生物基新材料列为关键战略材料，多项产业扶持政策持续落地。然 而，产业仍面临包括综合成本竞争力、原料供应链稳定、产品性能优化及终端市场接受度等关键问 题。 基于此， 2026年3月31日-4月1日 ，"第五届中国合成生物学及生物制造大会"将在杭州举办，其中设 置 【 生物基化学品与材料专场】 ，旨在汇聚产学研用多方智慧，破解产业发展难题，助力生物基 化学品与材料产业高质量发展。 承办单位 | 享融智云 商务合作 0 4 媒体支持 | synbio新农食、synbio新美护、synbio新材料、生物制造圈、合成生物学俱乐部 扫码 免费 报名参会 论坛设置 0 2 | | 会场一 | 会场二 | 会场三 | ...

Core Viewpoint - The article discusses the development of next-generation biomanufacturing technologies based on extreme microorganisms, particularly Halomonas bluephagenes, emphasizing their potential to achieve sustainable industrial production while addressing the challenges of traditional microbial platforms [2][3]. Group 1: Need for Biomanufacturing Transition - The biomanufacturing technology using microorganisms is increasingly recognized as an environmentally friendly alternative for producing diverse chemicals, driven by advancements in synthetic biology [8]. - Current industrial biotechnology faces limitations due to high energy-consuming sterilization processes and inefficiencies in continuous production, necessitating the shift to next-generation biomanufacturing (NGIB) using extreme microorganisms [9][10]. Group 2: Industrial Value of Extreme Microorganisms - Extreme microorganisms, such as thermophiles, acidophiles, and halophiles, exhibit remarkable growth capabilities in harsh environments, making them suitable for industrial applications [11]. - These microorganisms can significantly reduce sterilization needs and enhance production efficiency, positioning them as valuable assets in sustainable biomanufacturing [14][15]. Group 3: Development of Next-Generation Industrial Biotechnology - Halomonas bluephagenes, a halophilic bacterium, shows promise in producing biopolymers like PHB, with advantages in genetic engineering and metabolic pathway optimization [13][16]. - The development of genetic tools and adaptive evolution strategies has led to significant improvements in product yields and metabolic efficiency [17][20]. Group 4: Metabolic Engineering and Product Synthesis - Metabolic engineering is crucial for enhancing the production of target metabolites in extreme microorganisms, with strategies focusing on cell morphology optimization and dynamic control of protein degradation rates [20][21]. - Halomonas bluephagenes has been engineered to utilize various low-cost substrates, including starch and food waste, for the production of biopolymers and high-value chemicals [27][33]. Group 5: Industrial Applications and Future Directions - The NGIB technology has been successfully applied in the production of biodegradable materials like PHA and various fine chemicals, with industrial-scale implementations already underway [39]. - Future advancements will require integrating cutting-edge technologies and optimizing metabolic pathways to enhance the efficiency and sustainability of biomanufacturing processes [41][43].

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]

公司简介 招股书显示，引航生物是以技术创新为驱动的合成生物学引领者，致力于提供绿色可持续、高效生产且具备突出成本优势的生物基产品。公司的产品已在相 关市场占据领先地位。 据港交所2月12日披露，苏州引航生物科技股份有限公司(简称：引航生物)向港交所主板递交上市申请，华泰国际为其独家保荐人。 就原料药及中间体而言，根据灼识咨询，自2025年实现氟苯尼考的规模化生产后，以截至2025年9月30日止九个月的收入计，公司于同期的市场份额为 24.5%，位居全球氟苯尼考行业第二位；以截至2025年9月30日止九个月的收入(包括内部及外部销售)计算，公司的D-乙酯市场份额44.5%，位居全球D-乙酯 行业排名第一。 为支持产品创新与商业化，引航生物已构筑起"双引擎"研发能力，包括突破性原创工艺路线设计能力及基于AI辅助与高通量DBTL工作流程的高效合成生物 学工程化能力。原创工艺路线设计为目标化合物的开发奠定有商业可行性的适宜技术路径，而高效的合成生物学工程化能力可在实验室快速完成酶及菌株改 造，并推动规模化生产。这两者结合在一起，使公司能够持续开发出有竞争力的产品并保持高速增长。 引航生物的产品开发遵循技术驱动模式，基 ...

智通财经APP获悉，据港交所2月12日披露，苏州引航生物科技股份有限公司(简称：引航生物)向港交所主板递交上市申请，华泰国际为其独家保荐人。 公司简介 招股书显示，引航生物是以技术创新为驱动的合成生物学引领者，致力于提供绿色可持续、高效生产且具备突出成本优势的生物基产品。公司的产品已在相 关市场占据领先地位。 就原料药及中间体而言，根据灼识咨询，自2025年实现氟苯尼考的规模化生产后，以截至2025年9月30日止九个月的收入计，公司于同期的市场份额为 24.5%，位居全球氟苯尼考行业第二位；以截至2025年9月30日止九个月的收入(包括内部及外部销售)计算，公司的D-乙酯市场份额44.5%，位居全球D-乙酯 行业排名第一。 为支持产品创新与商业化，引航生物已构筑起"双引擎"研发能力，包括突破性原创工艺路线设计能力及基于AI辅助与高通量DBTL工作流程的高效合成生物 学工程化能力。原创工艺路线设计为目标化合物的开发奠定有商业可行性的适宜技术路径，而高效的合成生物学工程化能力可在实验室快速完成酶及菌株改 造，并推动规模化生产。这两者结合在一起，使公司能够持续开发出有竞争力的产品并保持高速增长。 引航生物的产品开发 ...